Recent Company News

• 08:34 AM ET Jun 25, 2025
  

  Biodexa Pharmaceuticals announces activation of first clinical study site for Phase 3 Serenta trial in Familial Adenomatous Polyposis (FAP) ($0.92, 0.00)

• 08:32 AM ET Jun 23, 2025
  

  Biodexa Pharmaceuticals unveils "Serenta" as the name of its upcoming Phase 3 study in Familial Adenomatous Polyposis (FAP) ($0.87, 0.00)

• 07:07 AM ET Jun 18, 2025
  

  Biodexa enrolls first patient in phase 2a study of its type 1 diabetes candidate tolimidone ($0.80, 0.00)

• 07:01 AM ET Jun 18, 2025
  

  Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

• 08:33 AM ET Jun 04, 2025
  

  Biodexa Pharmaceuticals announces recruitment of first patient in Phase 2 study of tolimidone in Type 1 diabetes ($1.16, 0.00)

• 08:32 AM ET May 30, 2025
  

  Biodexa Pharmaceuticals provides update on cash position and eRapa Phase 3 program ($1.06, 0.00)

• 08:32 AM ET May 22, 2025
  

  Biodexa Pharmaceuticals announces award of additional $3.0M grant from CPRIT to support registrational eRapa Phase 3 Program in FAP ($1.30, 0.00)

• 08:31 AM ET May 12, 2025
  

  Biodexa Pharmaceuticals receives orphan drug designation in Europe for eRapa in FAP ($1.41, 0.00)

• 08:35 AM ET Apr 11, 2025
  

  Biodexa Pharmaceuticals reports preliminary FY24 EPS (0.1p) vs year-ago (2p) ($1.57, 0.00)

• 07:16 AM ET Mar 19, 2025
  

  Biodexa Pharmaceuticals trading higher pre-open; issues press release on Phase 3 trial in FAP ($2.02, 0.00)